LOSEASONIQUE
Clinical safety rating
cautionComprehensive clinical and safety monograph for LOSEASONIQUE (LOSEASONIQUE).
Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.
| Metabolism | Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes conjugation and enterohepatic recirculation. Drospirenone: extensively metabolized by CYP3A4, with minor involvement of CYP1A1 and CYP2C9; forms two major metabolites (dihydrodrospirenone and drospirenone sulfate) that are not pharmacologically active. |
| Excretion | Renal: ~50% as metabolites; fecal: ~30% as metabolites; biliary: minor. |
| Half-life | Terminal elimination half-life is 12-15 hours, supporting once-daily dosing. |
| Protein binding | Ethinyl estradiol: ~97% bound to albumin; progestin: ~99% bound to SHBG and albumin. |
| Volume of Distribution | Ethinyl estradiol: 4-5 L/kg; progestin: 2-3 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~40-60% for ethinyl estradiol due to first-pass metabolism; progestin: >80%. |
| Onset of Action | Oral: 1-2 hours for peak serum concentrations; clinical effect (contraception) begins after 7 days of consistent dosing. |
| Duration of Action | 24 hours; adequate contraception requires daily dosing without missing pills. |
| Molecular Weight | 416.57 |
One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure. |
| Liver impairment | Contraindicated in Child-Pugh Class B or C hepatic impairment; no specific dose adjustment defined for mild impairment but use with caution. |
| Pediatric use | Safety and efficacy established in females of reproductive age; postmenarche use as per adult dosing. Not indicated before menarche. |
| Geriatric use | Not indicated for use in postmenopausal women; no geriatric-specific dosing. |
| 1st trimester | Contraindicated due to risk of fetal harm; animal studies show teratogenic effects and human data suggest possible teratogenicity. |
| 2nd trimester | Contraindicated due to potential adverse effects on fetal development and pregnancy outcomes. |
| 3rd trimester | Contraindicated during pregnancy; may cause fetal harm or complications. |
Clinical note
Comprehensive clinical and safety monograph for LOSEASONIQUE (LOSEASONIQUE).
| Placental transfer | Crosses the placenta; active metabolites are detectable in fetal tissues. |
| Breastfeeding | Excreted into human milk; use while breastfeeding is not recommended due to potential adverse effects on nursing infant. Alternative contraception should be considered. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects and limb reduction. Second and third trimester exposure may result in fetal harm including masculinization of female genitalia (progestin effect) and possible hepatic adenoma. Discontinue immediately if pregnancy occurs. |
| Fetal Monitoring | Perform pregnancy test before initiation. Monthly during first cycle, then every 3 months. Monitor for signs of thromboembolism, hypertension, hepatic dysfunction. Fetal ultrasound if inadvertent exposure. |
| Fertility Effects | Reversible suppression of ovulation. Return to baseline fertility typically within 1-3 months after discontinuation. No permanent impairment. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
Known or suspected pregnancyLactationUndiagnosed abnormal uterine bleedingKnown or suspected breast cancer or other estrogen-dependent neoplasiaActive liver disease or impaired liver functionHistory of thromboembolic disorders or thrombophlebitisKnown hypersensitivity to any component of the productUncontrolled hypertensionDiabetes with vascular involvementMigraine with focal auraHeadaches with focal neurological symptomsMajor surgery with prolonged immobilizationSmoking in women over 35 years of age
| Precautions | Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), Hepatic disease (acute hepatitis, benign/malignant liver tumors), Hypertension (contraindicated if uncontrolled), Gallbladder disease, Carbohydrate/lipid metabolism effects, Headache (including migraine with focal aura), Uterine bleeding irregularities, Depression, Fluid retention, Ocular lesions (retinal thrombosis), Cervical cancer screening, Hereditary angioedema, Chloasma, Drug interactions (especially CYP3A4 inducers), Laboratory test interference (sex hormone-binding globulin, thyroid-binding globulin) |
| Food/Dietary | No specific dietary restrictions. Grapefruit may slightly increase ethinyl estradiol levels; consistent intake is advised. Alcohol in moderation does not affect efficacy. Always take with or without food consistently. |
| Clinical Pearls | LOSEASONIQUE (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive with a shortened hormone-free interval (2 days of placebo vs. typical 7 days) to reduce withdrawal bleeding duration and frequency. Counsel patients that spotting/breakthrough bleeding may occur more commonly in the first few cycles. It does not protect against STIs. Consider alternative contraception in patients with contraindications like smoking >35, hypertension, migraine with aura, or history of thromboembolism. |
| Patient Advice | Take one tablet daily at the same time, even during placebo days, to maintain contraceptive efficacy. · If a dose is missed, follow the package instructions; missed pills increase pregnancy risk. · Spotting or breakthrough bleeding is common in the first 3 months and usually resolves. · Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots. · This medication does not protect against HIV or other sexually transmitted infections. · Use back-up contraception (e.g., condoms) if you have vomiting or severe diarrhea for more than 48 hours. · Report any signs of blood clots: sudden chest pain, shortness of breath, leg swelling/pain, or severe headache. |
Loading safety data…